Results 81 to 90 of about 202,263 (297)

Metabolic and Microvascular Risk Factors Associated With Brain Health in Type 1 Diabetes

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT We examined relationships between metabolic factors, microvascular complications, and brain health in adults with type 1 diabetes. Fifty‐one adults were assessed for metabolic risk factors, microvascular complications, and cognitive function, with a subset completing brain MRI.
Jihyun Park, Emily J. Koubek, Richard Beare, Lynn Ang, Brian C. Callaghan, Rodica Pop‐Busui, Eva L. Feldman, Evan L. Reynolds   +7 more
wiley   +1 more source

Computer‐assisted prediction of clinical progression in the earliest stages of AD

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2018
Introduction Individuals with subjective cognitive decline (SCD) are at increased risk for clinical progression. We studied how combining different diagnostic tests can help to identify individuals who are likely to show clinical progression.
Hanneke F.M. Rhodius‐Meester, Hilkka Liedes, Juha Koikkalainen, Steffen Wolfsgruber, Nina Coll‐Padros, Johannes Kornhuber, Oliver Peters, Frank Jessen, Luca Kleineidam, José Luis Molinuevo, Lorena Rami, Charlotte E. Teunissen, Frederik Barkhof, Sietske A.M. Sikkes, Linda M.P. Wesselman, Rosalinde E.R. Slot, Sander C.J. Verfaillie, Philip Scheltens, Betty M. Tijms, Jyrki Lötjönen, Wiesje M. van derFlier   +20 more
doaj   +1 more source

Unraveling 4‐Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw, Karishma Randhave, Ekta Anand, Ziang (Debbie) Song, Wangzhen Shen, Jing‐Qiong Kang   +5 more
wiley   +1 more source

Alzheimer\u2019s Disease and Related Dementias [Spanish]

Alzheimer\u2019s Disease and Related Dementias [Spanish]\ubfQu\ue9 es la enfermedad de Alzheimer? -- \ubfQui\ue9n la tiene? -- Lo que sabemos -- C\uf3mo reconocer los signos de la enfermedad de Alzheimer -- C\uf3mo se trata -- Apoyo para la familia y los

core  

Peripheral Neutrophil Activation and Extracellular Trap Formation in Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
Markers of neutrophil activation are increased in plasma during ALS, and markers of NET formation associate with ALS survival. ABSTRACT Objectives Peripheral neutrophil levels in amyotrophic lateral sclerosis (ALS) inversely correlate with survival, suggesting a role for neutrophils in disease progression.
Lillia A. Baird, Haley McQuown, Jihyun Park, Samuel J. Teener, Ian F. Webber‐Davis, Andrew D. Carter, Dae‐Gyu Jang, Eva L. Feldman, Stephen A. Goutman, Benjamin J. Murdock   +9 more
wiley   +1 more source

Dementia caregiving in Oregon: Data from the 2016 Behavioral Risk Factor Surveillance System

In Oregon, more than half of all adults providing unpaid care to loved ones with Alzheimer\u2019s or another dementia have been doing so for at least two years.This Fact Sheet is supported by Cooperative Agreement #NU58DP006115 from the Centers for ...

core  

Early Recognition of Treatment‐Responsive Rapidly Progressive Dementia: The Modified STAM3mP Score

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Early identification of patients with treatment‐responsive rapidly progressive dementia (RPD) is important as early treatment improves outcomes. The STAM3P score identifies treatment‐responsive RPD using “high risk” presenting features. We optimized performance by adding a time component (i.e., dementia within 3 months) and validated the ...
R. W. van Steenhoven, N. Satyadev, A. E. M. Bastiaansen, Y. D. Piura, J. Kerstens, Y. S. Crijnen, J. Brenner, T. Brand, T. M. Bienfait, S. Veenbergen, J. M. de Vries, F. J. de Jong, E. G. P. Dopper, P. A. E. Sillevis Smitt, H. Seelaar, G. S. Day, M. J. Titulaer   +16 more
wiley   +1 more source

Insights and recommendations for working collaboratively and improving care in Alzheimer's disease: Learnings from the Finding Alzheimer's Solutions Together (F.A.S.T.) Council

Health Expectations
Background Collaborations between patient organisations (POs) and the pharmaceutical industry can help identify and address the unmet needs of people living with a disease.
Jannice Roeser, Nikki Bayliss, Marco Blom, Ruth Croney, Lydia Lanman, Jerson Laks, Marco Lyons, Lea Proulx, Marianna Tsatali, Karin Westerlund, Jean Georges   +10 more
doaj   +1 more source

Dementia caregiving in Colorado: Data from the 2016 Behavioral Risk Factor Surveillance System

In Colorado, more than 40 percent of all adults providing unpaid care to loved ones with Alzheimer\u2019s or another dementia have been doing so for at least two years.This Fact Sheet is supported by Cooperative Agreement #NU58DP006115 from the Centers ...

core  

A Two‐Stage Questionnaire and Actigraphy Screening for iRBD in a Multicenter Retrospective Cohort

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Isolated rapid‐eye‐movement sleep behavior disorder is a prodromal marker of synucleinopathies. However, most cases remain undiagnosed due to the insufficient predictive value of questionnaires and limited access to confirmatory video‐polysomnography. We assessed a two‐stage screening strategy combining a brief questionnaire on rapid‐
Caleb A. Massimi, Giorgio Ricciardiello Mejia, Andre Metzger, Kang Hyun Ryu, Salonee Marwaha, Eva Grzegorczyk, Li Zhou, Eliana Jacobs, Boris Gilyadov, Claudia Kunney, Liqhwa Ncube, Ankit Parekh, Emmanuel Mignot, Fanny M. Elahi, Joseph Winer, Kathleen Poston, Andreas Brink‐Kjaer, Emmanuel H. During   +17 more
wiley   +1 more source